Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro.
about
Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunityTumor antigen-specific monoclonal antibodies and induction of T-cell immunityMonoclonal antibodies for the treatment of cancerImmunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapyEstablishment, characterization and chemosensitivity of three mismatch repair deficient cell lines from sporadic and inherited colorectal carcinomasThe anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cellsThe Role of Adaptive Immunity in the Efficacy of Targeted Cancer TherapiesHigh efficacy of CpG-ODN, cetuximab and cisplatin combination for very advanced ovarian xenograft tumors.Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients.Immunological off-target effects of standard treatments in gastrointestinal cancersIntegrating conventional and antibody-based targeted anticancer treatment into immunotherapyExploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy.Combining immunotherapy and targeted therapies in cancer treatment.Strategies for enhancing vaccine-induced CTL antitumor immune responses.Immunologic microenvironment and personalized treatment in multiple myeloma.Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer.Immature, Semi-Mature, and Fully Mature Dendritic Cells: Toward a DC-Cancer Cells Interface That Augments Anticancer ImmunityMyeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities.Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration.Immunotherapy of colorectal cancer: new perspectives after a long path.Immune modulation by dendritic-cell-based cancer vaccines.A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival.Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse.EGFR L2 domain mutation is not correlated with resistance to cetuximab in metastatic colorectal cancer patients.Chemotherapy ± cetuximab modulates peripheral immune responses in metastatic colorectal cancer.Preclinical modeling of EGFR-specific antibody resistance: oncogenic and immune-associated escape mechanisms.Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine.T cell receptor richness in peripheral blood increases after cetuximab therapy and correlates with therapeutic response
P2860
Q26862220-F84CF152-49BF-4E87-9424-8480CC19F7B5Q27009908-B55DB198-3F47-4620-AFC8-7ACCB3A67F16Q27025966-FE5944FC-664C-4F5B-BA10-98C68F88F302Q27027093-54D43FFD-F6D2-49D4-BE46-61A312ACB636Q28484668-711F83BF-CDAD-4F78-B7C7-BB675A22E06BQ35068059-A74C324B-E0A8-4C52-9A29-7C5B3E3C7940Q36535465-A0E0AB85-5693-42E1-99D1-AF7420B6173CQ36608597-C9F6D128-6C16-4391-A279-D8721AA9BBCBQ36821179-AF8D6F2E-E4E2-4D46-8EA1-5F9A96F8E4B2Q37404086-78763C4B-E3A6-4DC9-AF76-E246D6C3C90AQ37592814-2F456928-24AB-4A2B-8543-A2D773ADE75AQ37969356-CE890689-7821-41D7-81ED-54A64D616070Q37995939-7121DD02-FFA8-4DC3-99D9-5BA1EFA3CBDBQ38055143-6FAF09A5-F90E-49B2-A951-619780C91187Q38108390-5B035357-8A7D-4FFD-BA27-CCCBFC958C28Q38115968-D2C095F2-19E1-420B-8081-B4888CFC9455Q38174601-BB373AC2-BC8A-4D2F-AF80-DE43DE164177Q38299932-F30DEFCF-B5F2-4952-98D6-A81D9EEF6482Q38998238-D8DB139A-BCB8-41A4-8CE6-6E3CA6DDE3C2Q39043413-9B1D8D22-4237-4C6B-89B9-A21420E64914Q39147683-FB4D9536-13D0-4664-B79F-F3A0534AACE2Q41091865-757B5288-70A3-4CDF-A17B-171425BAD790Q42801569-91604DBE-53B2-47B7-9C9E-80EA732A61F6Q44702301-2C3B0915-55D7-43BE-9D60-670B94591827Q46009100-791BF884-8C4F-4AF8-BB3E-9281EBA986FDQ47704805-FE303176-D585-412E-8BB0-C61594341763Q54213155-E9AC9BD6-4FC0-441D-ABD4-E252F60E0675Q58129612-EE3E07DF-8AF8-4ABE-BC41-3EBA87B2CCA1
P2860
Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Cetuximab ± chemotherapy enhan ...... oxic T-cell response in vitro.
@en
Cetuximab ± chemotherapy enhan ...... oxic T-cell response in vitro.
@nl
type
label
Cetuximab ± chemotherapy enhan ...... oxic T-cell response in vitro.
@en
Cetuximab ± chemotherapy enhan ...... oxic T-cell response in vitro.
@nl
prefLabel
Cetuximab ± chemotherapy enhan ...... oxic T-cell response in vitro.
@en
Cetuximab ± chemotherapy enhan ...... oxic T-cell response in vitro.
@nl
P2093
P2860
P50
P921
P356
P1476
Cetuximab ± chemotherapy enhan ...... toxic T-cell response in vitro
@en
P2093
A Abbruzzese
L Bonmassar
M M De Santi
M T Del Vecchio
M Turriziani
P Tagliaferri
S Apollinari
P2860
P304
P356
10.1002/IJC.26181
P577
2011-08-16T00:00:00Z